Search Result

Isoforms Recommended:	JAK2

Results for "

JAK-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (241) Ack1 (1) Akt (3) Aldose Reductase (1) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (55) Arginase (1) Atg8/LC3 (3) Aurora Kinase (7) Autophagy (20) Bacterial (3) Bcl-2 Family (2) Bcr-Abl (6) Biochemical Assay Reagents (1) Btk (2) Caspase (3) CDK (6) COX (4) Cytochrome P450 (3) Deubiquitinase (2) Drug Derivative (1) Drug Intermediate (1) EGFR (3) Endogenous Metabolite (4) Epigenetic Reader Domain (2) ERK (2) FGFR (1) FLT3 (27) GSK-3 (4) HDAC (4) HIV (3) IFNAR (2) IKK (2) Interleukin Related (14) IRAK (1) Isotope-Labeled Compounds (7) Itk (1) JNK (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MEK (2) MHC (1) Microtubule/Tubulin (1) Mitosis (2) MMP (1) Monoamine Oxidase (2) mTOR (4) Na+/K+ ATPase (1) nAChR (2) NADH Dehydrogenase (1) NF-κB (7) NO Synthase (6) Orthopoxvirus (1) p38 MAPK (4) p62 (3) Parasite (1) PARP (1) PERK (1) PI3K (5) PKC (1) Polo-like Kinase (PLK) (3) PROTACs (7) Protease Activated Receptor (PAR) (1) Proteasome (1) Reactive Oxygen Species (ROS) (5) Reference Standards (15) RET (3) Small Interfering RNA (siRNA) (3) SOD (1) Src (1) STAT (51) Syk (7) TGF-beta/Smad (2) TGF-β Receptor (2) Thrombopoietin Receptor (2) TNF Receptor (7) Toll-like Receptor (TLR) (2) Trk Receptor (1) VEGFR (2) Virus Protease (1)
By Research Areas:	Cancer (169) Cardiovascular Disease (12) Infection (6) Inflammation/Immunology (97) Metabolic Disease (6) Neurological Disease (5)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

265

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-102055

JAK2 JH2 Tracer 5+ Cited Publications	JAK	Others
JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for **JAK2 JH2 domain, with a K_d** value of 0.2 μM ^[2].

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective **JAK2 JH2 binder, with a K_d** of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .

HY-15480

NSC 42834 2 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F* and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-RS07020

Jak2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
Jak2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Rat Pre-designed siRNA Set A Jak2 Rat Pre-designed siRNA Set A

HY-RS07018

JAK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
JAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

JAK2 Human Pre-designed siRNA Set A JAK2 Human Pre-designed siRNA Set A

HY-RS07019

Jak2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
Jak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Mouse Pre-designed siRNA Set A Jak2 Mouse Pre-designed siRNA Set A

HY-10652

JAK-2/3-IN-1	JAK	Inflammation/Immunology Cancer
JAK-2/3-IN-1 is a potent *JAK-2* and *JAK-3* inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-175684

JAK2-IN-14	JAK STAT Apoptosis	Cancer
JAK2-IN-14 is an orally active *JAK2* inhibitor with an IC₅₀ of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over *JAK1, JAK3, and TYK2, respectively. JAK2-IN-14* inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .

HY-176479

JAK2-IN-12	JAK	Cancer
JAK2-IN-12 (compound 23) is a *JAK2* inhibitor with a pIC₅₀ of 8.2. JAK2-IN-12 can be used for study of myelofibrosi .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active *JAK2* inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-137756

JAK2-IN-6 1 Publications Verification	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-100759

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

HY-169326S

JAK2-IN-11	Isotope-Labeled Compounds JAK	Cancer
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-161684

JAK2-IN-10	JAK	Cancer
JAK2-IN-10 (compound 5) is a potent JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM .

HY-117810

JAK2-IN-1	JAK	Inflammation/Immunology
JAK2-IN-1 (eExample 2) is a *JAK2* inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .

HY-161967

JAK2/FLT3-IN-3	FLT3 JAK Apoptosis	Cancer
JAK2/FLT3-IN-3 (11r) is a dual FLT3 and *JAK2* inhibitor, with IC₅₀ values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity .

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2/TYK2-IN-2* has anti-inflammatory activity .

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and *JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-131194

JAK2/STAT3-IN-1	Interleukin Related	Cancer
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

HY-130247B

Flonoltinib monomaleate JAK2/FLT3-IN-1 monomaleate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-130247

Flonoltinib 1 Publications Verification JAK2/FLT3-IN-1	JAK FLT3 Apoptosis	Cancer
Flonoltinib is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .

HY-151256

JAK-2/3-IN-2	JAK	Cancer
JAK-2/3-IN-2 (Compound 3h) is a *JAK2* and *JAK3* inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

HY-130247C

Flonoltinib sulfate JAK2/FLT3-IN-1 sulfate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib maleate has anti-cancer activity .

HY-130247A

Flonoltinib TFA 1 Publications Verification JAK2/FLT3-IN-1 TFA	JAK FLT3 Apoptosis	Cancer
Flonoltinib TFA is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity .

HY-P1590

*Tyrosine Protein Kinase JAK 2* (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-174428

*PROTAC JAK2* degrader-1**	JAK STAT PROTACs	Cancer
PROTAC JAK2 degrader-1 (Compound 10i) is a *JAK2* PROTAC degrader with a DC₅₀ of 27.35 nM for JAK2 V617F. PROTAC JAK2 degrader-1 promotes the ubiquitination and degradation of *JAK2. PROTAC JAK2* degrader-1 inhibits the phosphorylation of *JAK2, STAT3* and STAT5. PROTAC JAK2 degrader-1 can be used in the research of myeloproliferative neoplasms (Pink: JAK2 ligand (HY-174430); Blue: E3 ligase ligand (HY-W087383); Black: E3 ligase ligand + linker (HY-174432)) .

HY-156423

*Tubulin/JAK2-IN-1*	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-175611

*FLT3/JAK2/BRD4 ligand-1*	Ligands for Target Protein for PROTAC FLT3 JAK Epigenetic Reader Domain	Cancer
FLT3/JAK2/BRD4 ligand-1 is a *FLT3/JAK2/BRD4* ligand. FLT3/JAK2/BRD4 ligand-1 can be used for synthesis PROTAC FLT3/JAK2/BRD4 Degrader-1(HY-175610) .

HY-167839

*(R)-JAK2/STAT3-IN-1*	Apoptosis	Cancer
(R)-JAK2/STAT3-IN-1 is a GP130 D1 domain inhibitor with anti-tumor activity. (R)-JAK2/STAT3-IN-1 can inhibit the phosphorylation of JAK2 and STAT3. The affinity of (R)-JAK2/STAT3-IN-1 for GP130 protein is 3.8 μM. (R)-JAK2/STAT3-IN-1 effectively inhibits the viability and migration of tumor cells and promotes apoptosis .

HY-175610

*PROTAC FLT3/JAK2/BRD4 Degrader-1*	PROTACs FLT3 JAK Epigenetic Reader Domain	Cancer
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, *JAK2, and BRD4* with DC₅₀ values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC₅₀ = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .

HY-146066A

*(R)-α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Others
(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase Interleukin Related	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-120604

BVB808 NVP_BVB808	JAK STAT	Cancer
BVB808 (NVP_BVB808) is a selective *JAK2* inhibitor with approximately 10-fold selectivity for *JAK2* over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of *JAK2* and reduces the phosphorylation of STAT5, thereby blocking the *JAK2*-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research .

HY-18960

CHZ868 5+ Cited Publications	JAK	Cancer
CHZ868 is a type II *JAK2* inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-113573

Protosappanin A PTA	Interleukin Related JAK STAT	Inflammation/Immunology
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .

HY-112391

SD-1029 1 Publications Verification	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation ^[2].

HY-13775

XL019 5+ Cited Publications	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 ^[2].

HY-P10840

Tkip	JAK MHC	Inflammation/Immunology
Tkip is a *JAK2* specific inhibitor. Tkip can bind the *JAK2* autophosphorylation site, inhibit the *JAK2* autophosphorylation and the phosphorylation of the IFN-γ receptor subunit IFNGR-1. Tkip inhibits the antiviral activity of IFN-γ and the expression of MHC Class I molecules. Tkip can be used to study the IFN-γ signaling pathway .

HY-126141

JAK/HDAC-IN-1 1 Publications Verification	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-1 is a potent *JAK2/HDAC* dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC₅₀s of 4 and 2 nM for JAK2 and HDAC, respectively .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities ^[2] .

HY-115452

G5-7	JAK Apoptosis	Cancer
G5-7, an orally active and allosteric *JAK2* inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr ¹⁰⁶⁸) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-10410

TG101209 5 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-N1356

Reticuline 1 Publications Verification	JAK STAT NF-κB Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects ^[2].

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-147330

SJ1008030	PROTACs JAK	Cancer
SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 can be used for the research of leukemia .

HY-164393

ON044580	JAK Bcr-Abl Apoptosis	Cancer
ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive *JAK2* kinase inhibitor with IC₅₀s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 ^V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .

HY-10411

AZ960	JAK Apoptosis Parasite Virus Protease	Cancer
AZ960 is a potent and specific inhibitor of the *JAK2* kinase with a K_i of 0.45 nM.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113573

Protosappanin A PTA	Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Interleukin Related JAK STAT
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N1356

Reticuline 1 Publications Verification	Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm. Disease Research Fields	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects ^[2].

HY-N0635

Prim-O-glucosylcimifugin 4 Publications Verification	Natural Products Ophryosporus axilliflorus Hieron. Classification of Application Fields Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields	TNF Receptor NO Synthase COX
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and *COX-2* expression by through regulating JAK2/STAT3 signaling.

HY-N1535

Ponicidin 4 Publications Verification Rubescensine B	other families Classification of Application Fields Terpenoids Labiatae Source classification Diterpenoids Emilia sonchifolia (L.) DC. Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity. Ponicidin (Rubescensine B) induces apoptosis of gastric carcinoma cell, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3 .

HY-121471

Chrysoeriol 3 Publications Verification	Flavonoids Classification of Application Fields Flavones Phenols Polyphenols Metabolic Disease Euphorbiaceae Plants Brassicaceae Phyllanthus Disease Research Fields Coronopus didymus	Endogenous Metabolite
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity ^[2] .

HY-N2963

Broussonin E	Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Triterpenes Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK Reference Standards
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N13294

Cernuumolide J TMJ-105	Terpenoids Carpesium cernuum L. Sesquiterpenes Source classification Plants Compositae	Apoptosis JAK STAT p38 MAPK JNK ERK
Cernuumolide J (TMJ-105) is an *JAK2/STAT3* inhibitor. Cernuumolide J induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of *JAK2, STAT3, and Erk, and activating the phosphorylation of JNK* and p38 MAPK. Cernuumolide J inhibits HEL leukemia cell growth in a time- and concentration-dependent manner, with an IC₅₀ value of 1.79 μM. Cernuumolide J can be used for research in the field of anti-cancer therapy .

HY-N0635R

Prim-O-glucosylcimifugin (Standard)	Natural Products Ophryosporus axilliflorus Hieron. Source classification Umbelliferae Plants	TNF Receptor Reference Standards NO Synthase COX
Prim-O-glucosylcimifugin (Standard) is the analytical standard of Prim-O-glucosylcimifugin. This product is intended for research and analytical applications. Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-N7452

Coumermycin A1 Maximum Cited Publications 17 Publications Verification	Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N15564

Theleganbanin B	Microorganisms Source classification Phenols Polyphenols	Drug Derivative
Theleganbanin B is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin B inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin B inhibits the phosphorylation of JAK2/STAT3. Theleganbanin B is promising for research of neurodegenerative diseases .

HY-121471R

Chrysoeriol (Standard)	Flavonoids Flavones Phenols Polyphenols Euphorbiaceae Plants Brassicaceae Phyllanthus Coronopus didymus	Reference Standards Endogenous Metabolite
Chrysoeriol (Standard) is the analytical standard of Chrysoeriol. This product is intended for research and analytical applications. Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity ^[2] .

HY-N0678

Icaritin 5 Publications Verification Anhydroicaritin	Flavonols Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	JAK Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[2] ^[3.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	other families Classification of Application Fields Source classification Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation ^[2] .

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	other families Source classification Other Phenylpropanoids Phenylpropanoids Plants	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation ^[2] .

HY-N1356A

(R)-Reticuline	Alkaloids Source classification Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	Cytochrome P450
(R)-Reticuline is an isomer of Reticuline (HY-N1356). Reticuline displays anti-inflammatory and cardiovascular effects through JAK2/STAT3 and NF-κB signaling pathways. Salutaridine is a key intermediate in morphine biosynthesis. Salutaridine can be converted from (R)-Reticuline in the poppy plant. The conversion system relies on membrane-bound cytochrome P-450 enzymes and also requires reducing cofactors NADPH, molecular oxygen, etc ^[2].

HY-N0678R

Icaritin (Standard) Anhydroicaritin (Standard)	Flavonols Human Gut Microbiota Metabolites Flavonoids Source classification Phenols Polyphenols Epimedium brevicornu Maxim. Plants Endogenous metabolite Berberidaceae	JAK Reference Standards Autophagy Apoptosis
Icaritin (Standard) is the analytical standard of Icaritin. This product is intended for research and analytical applications. Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 μM) and primary CML cells (IC₅₀ of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[2][3.

HY-N0201

Atractylenolide I 5 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	TNF Receptor Toll-like Receptor (TLR) JAK STAT
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated *JAK2* and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N0807

Swertiamarin	Monophenols other families Classification of Application Fields Phenols Zanthoxylum chiloperone var. angustifolium Metabolic Disease Plants Disease Research Fields Cancer	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the *Nrf2/HO-1* pathway. Swertiamarin can attenuate inflammatory mediators by regulating *JAK2/STAT3* transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis ^[2] .

HY-N0201R

Atractylenolide I (Standard)	Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae	TNF Receptor Reference Standards Toll-like Receptor (TLR) JAK STAT
Atractylenolide I (Standard) is the analytical standard of Atractylenolide I. This product is intended for research and analytical applications. Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N2515

Ginsenoside Rk1 5+ Cited Publications	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB ^[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N2282

Zingiberen newsaponin Zingiberensis newsaponin	Cardiovascular Disease Triterpenes Classification of Application Fields Terpenoids Source classification Dioscorea Zingiberensis C.H.Wright Plants Disease Research Fields Dioscoreaceae	Aldose Reductase JAK STAT Autophagy Apoptosis NF-κB SOD Reactive Oxygen Species (ROS)
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the *AKR1C1/JAK2/STAT3* pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation ^[2] .

HY-N2515R

Ginsenoside Rk1 (Standard)	Panax ginseng C. A. Meyer Triterpenes Terpenoids Source classification Plants Araliaceae	Reference Standards NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB ^[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Animals Classification of Application Fields Source classification Other Diseases Disease Research Fields Steroids	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, *JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail* and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models ^[2] .

Cat. No.	Product Name	Chemical Structure

HY-169326S

JAK2-IN-11
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-161684

JAK2-IN-10
JAK2-IN-10 (compound 5) is a potent JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM .

HY-W062703S

(Rac)-Ruxolitinib-d9
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-16379S

Pacritinib-d4
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active *JAK1* and *JAK2* inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2] .

HY-10961S8

Momelotinib-d4 dihydrochloride hydrate
Momelotinib-d₄ (CYT387-d₄) dihydrochloride hydrate is a deuterium labeled Momelotinib (HY-10961). Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀s of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3 .

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis ^[2].

HY-103018S

Gusacitinib-d4

Gusacitinib-d₄ (ASN-002-d₄) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma ^[2].

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks